Evusheld drug approved for use in people aged 12 and older who are immunocompromised or for whom COVID-19 vaccination is not recommended.
Health Canada has authorized a drug developed by AstraZeneca to prevent COVID-19 infections.
Evusheld has been cleared for people aged 12 and older who have a compromised immune system and are unlikely to get an adequate response to a COVID-19 vaccination, or for whom COVID-19 vaccination is not recommended.
The medication contains lab-made antibodies designed to remain in the body for months, which officials say will contain the virus if there is an infection.
The therapy has also been authorized in the United States and has been recommended by the European Medicines Agency.